nevakar
announces
fda
approval
ephedrine
sulfate
injection
vials
bridgewater
globe
newswire
nevakar
biopharmaceutical
company
developing
multiple
assets
ophthalmic
injectable
areas
announced
today
received
approval
food
drug
administration
fda
market
ephedrine
sulfate
injection
ml
single
use
vial
presentation
exclusive
licensing
agreement
endo
international
nasdaq
endp
subsidiary
endo
ventures
limited
par
pharmaceuticals
sterile
products
division
launch
distribute
product
first
approval
previously
announced
collaboration
nevakar
endo
development
five
differentiated
sterile
injectable
products
canada
terms
agreement
nevakar
responsibility
develop
obtain
fda
approval
products
par
pharmaceuticals
sterile
products
division
launch
distribute
products
pleased
received
approval
convenient
patent
pending
form
frequently
used
treatment
clinically
important
hypotension
anesthesia
value
strong
partnership
endo
respected
pharmaceutical
company
significant
growing
presence
sterile
critical
care
products
pursue
mission
develop
innovative
pharmaceutical
products
improve
patient
care
quality
life
stated
navneet
puri
founder
chairman
chief
executive
officer
nevakar
nevakar
nevakar
growing
fully
integrated
biopharmaceutical
company
extensive
portfolio
products
ophthalmic
injectable
areas
founded
headquartered
bridgewater
new
jersey
company
focused
developing
commercializing
innovative
products
address
unmet
medical
needs
thereby
improving
patient
care
quality
life
nevakar
utilizes
b
regulatory
pathway
along
proven
expertise
development
novel
proprietary
sterile
pharmaceutical
products
identify
develop
obtain
regulatory
approval
products
additional
information
available
investor
contacts
marshall
woodworth
chief
financial
officer
e
mwoodworth
lisa
wilson
e
lwilson
